Outset Medical Inc (OM)

$5.7

+0.01

(+0.18%)▲

Market is closed - opens 8 PM, 05 Dec 2023

Insights on Outset Medical Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 36.04M → 30.36M (in $), with an average decrease of 15.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -40.78M → -46.18M (in $), with an average decrease of 3.2% per quarter

  • Vs SYK

    In the last 1 year, Stryker Corporation has given 22.5% return, outperforming this stock by 96.8%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 24.3% return, outperforming this stock by 113.3%

Performance

  • $5.67
    $6.04
    $5.70
    downward going graph

    0.53%

    Downside

    Day's Volatility :6.1%

    Upside

    5.6%

    downward going graph
  • $2.90
    $30.55
    $5.70
    downward going graph

    49.12%

    Downside

    52 Weeks Volatility :90.51%

    Upside

    81.34%

    downward going graph

Returns

PeriodOutset Medical IncSector (Health Care)Index (Russel 2000)
3 Months
-57.44%
-1.3%
0.0%
6 Months
-73.68%
1.2%
0.0%
1 Year
-73.44%
-5.7%
-6.5%
3 Years
-88.99%
17.1%
-6.5%

Highlights

Market Capitalization
247.5M
Book Value
$3.03
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.56
Wall Street Target Price
7.4
Profit Margin
-133.19%
Operating Margin TTM
-149.71%
Return On Assets TTM
-31.98%
Return On Equity TTM
-81.47%
Revenue TTM
131.9M
Revenue Per Share TTM
2.68
Quarterly Revenue Growth YOY
9.4%
Gross Profit TTM
17.8M
EBITDA
-166.6M
Diluted Eps TTM
-3.56
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.74
EPS Estimate Next Year
-2.05
EPS Estimate Current Quarter
-0.67
EPS Estimate Next Quarter
-0.65

Analyst Recommendation

Buy
    66%Buy
    26%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Outset Medical Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
11
11
Hold
4
4
3
Sell
1
00
00

Analyst Forecast

What analysts predicted

Upside of 29.82%

Current $5.70
Target $7.40

Company Financials

FY18Y/Y Change
Revenue
2.0M
-
Net Income
-49.8M
-
Net Profit Margin
-2.5K%
-
FY19Y/Y Change
Revenue
15.1M
↑ 651.27%
Net Income
-68.3M
↑ 37.2%
Net Profit Margin
-452.97%
↑ 2027.35%
FY20Y/Y Change
Revenue
49.9M
↑ 231.18%
Net Income
-120.7M
↑ 76.72%
Net Profit Margin
-241.71%
↑ 211.26%
FY21Y/Y Change
Revenue
102.6M
↑ 105.47%
Net Income
-131.9M
↑ 9.31%
Net Profit Margin
-128.59%
↑ 113.12%
FY22Y/Y Change
Revenue
115.4M
↑ 12.45%
Net Income
-163.0M
↑ 23.51%
Net Profit Margin
-141.24%
↓ 12.65%
Q2 FY22Q/Q Change
Revenue
25.1M
↓ 17.98%
Net Income
-43.8M
↑ 18.83%
Net Profit Margin
-174.96%
↓ 54.2%
Q3 FY22Q/Q Change
Revenue
27.8M
↑ 10.79%
Net Income
-40.8M
↓ 6.98%
Net Profit Margin
-146.9%
↑ 28.06%
Q4 FY22Q/Q Change
Revenue
32.0M
↑ 15.29%
Net Income
-41.4M
↑ 1.63%
Net Profit Margin
-129.48%
↑ 17.42%
Q1 FY23Q/Q Change
Revenue
33.5M
↑ 4.56%
Net Income
-44.0M
↑ 6.1%
Net Profit Margin
-131.39%
↓ 1.91%
Q2 FY23Q/Q Change
Revenue
36.0M
↑ 7.69%
Net Income
-44.0M
↑ 0.17%
Net Profit Margin
-122.21%
↑ 9.18%
Q3 FY23Q/Q Change
Revenue
30.4M
↓ 15.75%
Net Income
-46.2M
↑ 4.84%
Net Profit Margin
-152.1%
↓ 29.89%
FY18Y/Y Change
Total Assets
151.1M
-
Total Liabilities
439.1M
-
FY19Y/Y Change
Total Assets
88.4M
↓ 41.53%
Total Liabilities
460.6M
↑ 4.89%
FY20Y/Y Change
Total Assets
403.8M
↑ 357.0%
Total Liabilities
75.2M
↓ 83.67%
FY21Y/Y Change
Total Assets
463.5M
↑ 14.77%
Total Liabilities
89.4M
↑ 18.83%
FY22Y/Y Change
Total Assets
400.1M
↓ 13.67%
Total Liabilities
154.1M
↑ 72.43%
Q2 FY22Q/Q Change
Total Assets
401.2M
↓ 7.07%
Total Liabilities
91.5M
↑ 6.01%
Q3 FY22Q/Q Change
Total Assets
365.7M
↓ 8.85%
Total Liabilities
86.6M
↓ 5.31%
Q4 FY22Q/Q Change
Total Assets
400.1M
↑ 9.4%
Total Liabilities
154.1M
↑ 77.93%
Q1 FY23Q/Q Change
Total Assets
362.7M
↓ 9.36%
Total Liabilities
146.4M
↓ 5.03%
Q2 FY23Q/Q Change
Total Assets
334.4M
↓ 7.78%
Total Liabilities
151.3M
↑ 3.39%
Q3 FY23Q/Q Change
Total Assets
307.6M
↓ 8.04%
Total Liabilities
155.5M
↑ 2.74%
FY18Y/Y Change
Operating Cash Flow
-46.4M
-
Investing Cash Flow
-68.8M
-
Financing Cash Flow
134.9M
-
FY19Y/Y Change
Operating Cash Flow
-70.3M
↑ 51.35%
Investing Cash Flow
74.3M
↓ 208.03%
Financing Cash Flow
249.0K
↓ 99.82%
FY20Y/Y Change
Operating Cash Flow
-99.0M
↑ 40.86%
Investing Cash Flow
3.9M
↓ 94.69%
Financing Cash Flow
385.7M
↑ 154792.37%
FY21Y/Y Change
Operating Cash Flow
-130.3M
↑ 31.56%
Investing Cash Flow
-142.5M
↓ 3710.51%
Financing Cash Flow
160.1M
↓ 58.48%
FY22Y/Y Change
Operating Cash Flow
-145.7M
↑ 11.87%
Investing Cash Flow
-66.3M
↓ 53.48%
Financing Cash Flow
72.9M
↓ 54.48%
Q2 FY22Q/Q Change
Operating Cash Flow
-38.6M
↑ 0.63%
Investing Cash Flow
-1.3M
↓ 96.06%
Financing Cash Flow
1.0M
↓ 72.01%
Q3 FY22Q/Q Change
Operating Cash Flow
-34.3M
↓ 11.05%
Investing Cash Flow
20.2M
↓ 1631.84%
Financing Cash Flow
2.5M
↑ 143.09%
Q4 FY22Q/Q Change
Operating Cash Flow
-34.5M
↑ 0.57%
Investing Cash Flow
-51.7M
↓ 356.7%
Financing Cash Flow
65.6M
↑ 2489.81%
Q1 FY23Q/Q Change
Operating Cash Flow
-44.8M
↑ 29.7%
Investing Cash Flow
2.6M
↓ 105.11%
Financing Cash Flow
5.3M
↓ 91.96%

Technicals Summary

Sell

Neutral

Buy

Outset Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Outset Medical Inc
Outset Medical Inc
33.26%
-73.68%
-73.44%
-88.99%
-90.62%
Stryker Corporation
Stryker Corporation
7.57%
7.13%
25.17%
24.29%
72.88%
Dexcom, Inc.
Dexcom, Inc.
22.96%
-6.45%
0.05%
34.03%
264.69%
Boston Scientific Corp.
Boston Scientific Corp.
6.31%
9.22%
23.6%
63.15%
53.72%
Abbott Laboratories
Abbott Laboratories
10.4%
1.08%
-0.5%
-2.8%
46.69%
Medtronic Plc
Medtronic Plc
8.95%
-4.47%
1.52%
-29.74%
-17.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Outset Medical Inc
Outset Medical Inc
NA
NA
NA
-2.74
-0.81
-0.32
0.0
3.03
Stryker Corporation
Stryker Corporation
43.5
43.5
2.85
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
124.12
124.12
11.34
1.42
0.18
0.06
0.0
5.87
Boston Scientific Corp.
Boston Scientific Corp.
67.84
67.84
2.53
2.01
0.07
0.04
0.02
12.89
Abbott Laboratories
Abbott Laboratories
34.99
34.99
18.76
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.64
25.64
3.04
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Outset Medical Inc
Outset Medical Inc
Buy
$247.5M
-90.62%
NA
-133.19%
Stryker Corporation
Stryker Corporation
Buy
$111.6B
72.88%
43.5
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$43.1B
264.69%
124.12
11.08%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$81.5B
53.72%
67.84
8.93%
Abbott Laboratories
Abbott Laboratories
Buy
$178.6B
46.69%
34.99
12.92%
Medtronic Plc
Medtronic Plc
Buy
$105.1B
-17.1%
25.64
12.84%

Institutional Holdings

  • FMR Inc

    14.89%

  • JPMorgan Chase & Co

    10.18%

  • Vanguard Group Inc

    9.51%

  • BlackRock Inc

    7.41%

  • T. Rowe Price Investment Management,Inc.

    6.31%

  • Bellevue Group AG

    4.80%

Corporate Announcements

  • Outset Medical Inc Earnings

    Outset Medical Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

outset is a pioneering medical technology company that always puts the patient before the machine. our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. and to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. because we believe a dialysis machine should be as easy to use as an everyday consumer product, tablo was designed with simplicity in mind. one example is tablo’s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. and with simplicity comes speed. we’ve set out to give people their time back. tablo dramatically reduces

Organization
Outset Medical Inc
Employees
518
CEO
Ms. Leslie L. Trigg
Industry
Health Technology

Discover More

FAQs